Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Biotechnology

Healthcare
$3.99 +1.53%

+$0.10 today

Market cap
$1.30B
Beta
1.18
P/E (TTM)
-17.7
EPS (TTM)
-$0.35
52W Low $2.25High $7.30

Volume 3.38M

Average 2.73M

TSHA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Taysha Gene Therapies, Inc.NASDAQ: TSHA

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin not reported for Q2 FY2026

Over 3 fiscal years it widened by 99.4 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
—— QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
LTMJun 2026
84.0%-16.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+0.0 pp——
3 years+99.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How TSHA compares with its peers on the latest reported figures

  • TSHA's LTM Jun 2026 gross margin of 84.0% is the highest of the 6 companies compared; the peer median is -0.1%.
  • Its year-over-year change of -16.0 pp is the 3rd highest of 5, against a peer median of -8.6 pp.
  • Over three fiscal years its change of +99.4 pp compares with a peer median of +36.5 pp.
TSHA Competitors Peer median
Gross Margin for TSHA and competitors
Company Period LTM level YoY 3-year change
TSHATaysha Gene Therapies, Inc.LTM Jun 202684.0% -16.0 pp+99.4 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 202662.4% -19.4 pp-25.1 pp
ABEOAbeona Therapeutics Inc.LTM Mar 202651.9% —+5.5 pp
RGNXREGENXBIO Inc.LTM Mar 2026-0.1% -76.7 pp+36.5 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-12.4% +490439.7 pp+2555.9 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-86.7% +2.3 pp+136.3 pp
NGNENeurogene Inc.FY2025— ——
BNTCBenitec Biopharma Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding TSHA) -0.1%-8.6 pp+36.5 pp

Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue02.5M15.45M8.33M9.77M
Cost of Revenue02.49M000
Gross Profit015K15.45M8.33M9.77M
Gross Margin—0.6%100.0%100.0%100.0%
Research & Development131.94M91.17M56.78M66M86.4M
Selling, General & Admin41.32M34.87M30.05M28.95M33.87M
Operating Expenses173.27M126.04M87.89M99.79M120.27M
Depreciation & Amortization492K2.49M1.37M1.25M1.15M
EBITDA(172.6M)(159.73M)(105.2M)(87.95M)(107.79M)
EBITDA Margin—-6384.1%-680.8%-1055.5%-1102.9%
Operating Income(173.27M)(126.03M)(72.44M)(91.46M)(110.5M)
Operating Margin—-5037.1%-468.8%-1097.6%-1130.6%
Interest Income172K249K3.57M6.94M9.22M
Interest Expense1.43M3.8M5M102K63K
Other Income / Expenses(1.26M)(39.99M)(39.13M)2.16M1.5M
Income Before Tax(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Pre-Tax Margin—-6635.3%-722.1%-1071.6%-1115.3%
Income Tax Expense00000
Net Income(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Net Margin—-6635.3%-722.1%-1071.6%-1115.3%
EPS (Basic)(4.64)(3.78)(0.96)(0.36)(0.34)
EPS (Diluted)(4.64)(3.78)(0.96)(0.36)(0.34)
Weighted Avg Shares37.65M43.95M116.12M250.13M319.71M
Weighted Avg Shares (Diluted)37.65M43.95M116.12M250.13M319.71M

Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Intrinsic Alpha fair value

Locked

Current Price

$3.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.